Login / Signup

Effect of the P-selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.

Scott D SolomonCharles J LowensteinAnkeet S BhattAlexander PeikertOrly VardenyMikhail Naum KosiborodJeffrey S BergerHarmony R ReynoldsStephanie MavromichalisAnya BarytolAndrew D AlthouseJames F LutherEric S LeiferAndrei L KindzelskiAndrea N EdgintonMichelle Ng GongLucy Z KornblithPooja KhatriKeri S KimLisa Baumann KreuzigerLana WahidBridget-Anne KirwanMark W GeraciMatthew D NealJudith S Hochmannull null
Published in: Circulation (2023)
Crizanlizumab, a P-selectin inhibitor, did not result in improvement in organ-support free days in patients hospitalized with COVID-19.
Keyphrases
  • end stage renal disease
  • coronavirus disease
  • ejection fraction
  • sars cov
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes